Scalper1 News
Medical-products company Mallinckrodt agreed to buy specialty drugmaker Questcor Pharmaceuticals for $5.6 billion Monday, a move that made Questcor investors happy but was more controversial in the Mallinckrodt camp. Mallinckrodt’s stock fell 2.5%, while Questcor’s jumped 19% to 80.58. Although Mallinckrodt (MNK) is the buyer, on the conference call with analysts the two CEOs spoke of it as a merger. The company will be renamed Mallinckrodt Scalper1 News
Scalper1 News